Verition Fund Management
APLS

Verition Fund Management’s Apellis Pharmaceuticals APLS Stock Holding History

Verition Fund Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-51,000
Closed -$1.56M – 597
2019
Q4 		$1.56M Buy
+51,000
New +$1.41M 0.03% 330

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Verition Fund Management's APLS Position: Q2 2026 in Review

Verition Fund Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 400,000 shares — an estimated $16.1M sold.

Verition Fund Management first reported a position in APLS in Q4 2019 and held it in 14 quarters. The position peaked at $16.1M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Verition Fund Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Verition Fund Management sold 400,000 Apellis Pharmaceuticals shares in Q2 2026, an estimated $16.1M.
  • Verition Fund Management first reported a position in Apellis Pharmaceuticals in Q4 2019 and held it in 14 quarters.
  • Verition Fund Management's Apellis Pharmaceuticals position peaked at $16.1M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.